RESULTS OF PRIMARY PREVENTION IN CERVICAL CANCER. ANTI-HPV VACCINATION. UPDATE OF FIGO CLASSIFICATION IN CERVICAL CANCER (2018)
Abstract:
Cervical cancer is considered a major public health problem, 90% of deaths due to this neoplasia occur in the developing countries. Cervical cancer is the second type of cancer diagnosed in the genital cancers’ hierarchy and the third cause of death due to cancer among the female population. In Romania, the incidence of cervical cancer and the mortality caused by this type of cancer is increased. In 2018, Globocan reports a number of 3308 newly diagnosed cases of cervical cancer in Romania. HPV infection is the main cause (99%) of cervical tumours and neoplastic precursor lesions, being also a sexually transmitted disease. Therefore, primary prevention programmes (HPV vaccination, immunization) and secondary prevention - cervical cytology screening, co-tests - primary HPV phenotyping and immunocytochemistry - histochemical biomarkers detection have been implemented worldwide. It is important to emphasize the results reported in 2018, of huge importance for the general population health, implemented by Australia, through the National Vaccination Programme, with quadrivalent vaccine (4v HPV 6,11,16,18), initiated in 2007 for female sex and extended since 2013 to the male sex. Conclusion of the Australian National Vaccination Programme: viral removal and eradication of HPV disease, thus demonstrating the efficacy and feasibility of the primary prevention programme.
full text article in English (.EN) |